Michèle Barzach
Corporate Officer/Principal bij International AIDS Vaccine Initiative, Inc.
Actieve functies van Michèle Barzach
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Corporate Officer/Principal | 30-11-2010 | - |
Loopbaan van Michèle Barzach
Eerdere bekende functies van Michèle Barzach
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| GSK PLC | Directeur/Bestuurslid | 01-01-1997 | 17-05-2004 |
| Independent Dir/Board Member | 01-01-1997 | 17-05-2004 |
Statistieken
Internationaal
| Verenigd Koninkrijk | 2 |
| Verenigde Staten | 2 |
Operationeel
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GSK PLC | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
- Beurs
- Insiders
- Michèle Barzach
- Ervaring